MUMBAI, India, July 30 -- Intellectual Property India has published a patent application (202631083469 A) filed by Dr. Soumya Ranjan Jena on July 07, 2026, for "neurocancel-X" A Low-Cost Early-Stage Cancer Detection And Prevention System And Method Thereof For Mankind.
Inventor includes Dr. Soumya Ranjan Jena.
The application for the patent was published on July 24, 2026, under issue no. 30/2026.
Abstract: The present invention discloses NEUROCANCEL-X, low-cost early-stage cancer detection and prevention system that integrates neuromorphic computing with multi- modal biomarker sensing for accessible cancer screening. The system includes neuromorphic processing unit (NPU-Mini) implementing spiking neural network on an FPGA operating below 10 mW, enabling fast and energy-efficient analysis. An integrated biomarker sensing module combines electrochemical liquid biopsy, breath volatile organic compound (VOC) analysis, and microbiome profiling, while Bayesian multi-modal fusion engine enhances diagnostic accuracy by integrating evidence across independent modalities. A wearable microneedle-based patch continuously samples interstitial fluid for seven-day biomarker monitoring. The system employs federated learning with differential privacy to preserve patient confidentiality by eliminating raw data transfer. NEUROCANCEL-X achieves 89.3% pan-cancer sensitivity and 95.2% specificity, delivers results in under three minutes, costs only $2–4 per test, and can be deployed through village health units at $40–60 per device, enabling affordable, scalable screening in low- and middle-income countries.
Disclaimer: Curated by HT Syndication.
